Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More EU review of GM crop cultivation applications

Long-running applications for EU cultivation of three genetically modified insect-resistant maize lines have been returned for yet another assessment by the European Food Safety Authority (EFSA), reports Agrow’s sister publication, Agra Europe . The European Commission has requested a reassessment of Syngenta’s Bt11 and DuPont/Dow AgroSciences’ 1507 (Herculex I), which were first given a positive evaluation by the EFSA in 2005. The third application concerns the renewal of the approval of Monsanto’s insect-resistant MON810, for which the EFSA gave safety clearance in 2009. The Authority has already issued several updates of its opinions on the GM lines, with the latest being in late 2011 ( Agrow No 631, p 8). However, the Commission says that another reassessment is needed to take account of the revision of the EFSA’s environmental risk assessment guidelines, issued in late 2010 ( Agrow No 604, p 10).

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG006495

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel